Effect of Jieze No.1(洁泽Ⅰ号)on Cervicitis Caused by Ureaplasma Urealyticum and on Ureaplasma Urealyticum in vitro

Objective:To observe the clinical therapeutic effect of Jieze No.1(洁泽Ⅰ号)on cervicitis caused by ureaplasma urealyticum and its inhibitory effect on ureaplasma urealyticum (Uu)in vitro.Methods:A total of 393 patients suffering from cervicitis induced by ureaplasma urealyticum without other complications were randomly assigned to 3 groups,the combined treatment group:140 patients treated with Chinese herbs Jieze No.1 by vaginal lavage,30 min each time,once a day for 10 consecutive days and oral administration of Azithromycin,1.0 g once every 72 h for three times;Jieze group:115 patients were treated with Jieze No.1 alone by vaginal lavage,30 min each time,once a day for 10 consecutive days;and the Azithromycin group:138 patients were treated with oral administration of Azithromycin,1.0 g once in 72 h for three times.All the patients were treated for 1 therapeutic course and condom were used for contraception during the treatment course.The Uu patients were examined again after 21 days of treatment.The therapeutic effect on cervicitis was observed.The experimental study of Jieze No.1 on the Uu strain separated from the secretion of the urogenital tract was also observed.The minimum inhibitory concentration(MIC)and minimum bactericidal concentration(MBC)of the Uu were investigated.Results:The total effective rate of the combined group was 85.3%,showing a significant difference compared with the Jieze group(67.8%)and the Azithromycin group(60.3%,both P＜0.01).There was no statistical significance between the latter two groups(P＞0.05).The clearing rate of Uu in the combined group was 78.4%,that of the Jieze group was 60.9%and the Azithromycin group was 47.9%.The combined group also showed a significant difference in comparison with the other two groups(all P＜0.01).Especially for the drugresistant strain,the clearing rate of Uu reached 48.1%in the combined group,42.1%in the Jieze group,and 16.1%in the Azithromycin group,respectively.The clearing rate of Uu for the drugresistant strain in the former two groups had significant differences in comparison with the latter (P＜0.01,P＜0.05),while there was no significant difference between the former two(P＞0.05).The range of MIC and MBC of Jieze No.1 to the drug-resistant strain of Uu was 15.62-250.00 mg/mL.To the non-drug-resistant MIC and MBC strain,it was 15.62-125.00 mg/mL.For the drug-resistant strain,MIC50 was≤31.25 mg/mL,MBC50 was≤62.50 mg/mL,MIC90 was≤1 25.00 mg/mL and MBC90 was≤250.00 mg/mL.For the non-drug-resistant strain,MICso was≤31.25 mg/mL,MBC50 was≤62.50 mg/mL,MIC90 was≤62.50 mg/mL and MBC90 was≤1 25.00 mg/mL.Conclusion:Jieze No.1 combined with Azithromycin can effectively treat cervicitis caused by Uu.The laboratory study confirms that Jieze No.1 has an inhibitory effect on ureaplasma uraalyticum strain.It has a remarkably effective therapeutic effects on drug-resistant strains,which is worthy of further research.     

A Clinical Study on the Effect of Yinxing Damo (银杏达莫) Combined with Betahistine Hydrochloride Injection on Vertebral Basilar Artery Ischemic Vertigo

Objective: To evaluate the therapeutic efficacy of Yinxing Damo (银杏达莫, YXDM) combined with Betahistine Hydrochloride Injection (BHI) on vertebra basilar artery ischemic vertigo (VBIV).Methods: Ninety patients with VBIV were randomly divided into two groups; 45 patients (the treated group)were treated with YXDM and BHI intravenous dripping, once a day for 14 days. Another 45 patients (control clinical syndromes and the index of the transcranial Doppler (TCD) and hemorheology were observed. Results: The total effective rate was 100% in the treated group, which was better than that in the control group90.5%, (P＜0.05). The indexes of TCD and hemorheology in the treated group were obviously improved after treatment, (P＜0.01). Conclusion: YXDM combined with BHT injection had better effect in treating patients with VBIV is an ideal drug for VBIV.     

Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine

Objective:To observe the clinical efficacy and adverse reactions of Paroxetine combined with electro-acupuncture (EA) in treating depression.Methods:Forty-two patients with depression were randomly assigned to the observation group (22 patients) treated with EA combined with Paroxetine,and the control group (20 patients) treated with Paroxetine alone,and the therapeutic course for both groups was 6 weeks.The therapeutic efficacy and adverse reactions were evaluated with scores by Hamilton depression scale (HAMD) and treatment emergent symptoms scale (TESS), respectively.Results:HAMD scores determined at the end of the 1st,2nd,4th,and 6th week of the treatment course were significantly lower in the observation group than those in the control group (P<0.05).The significant improvement rate evaluated at the end of the 6-week treatment was remarkably higher in the observation group than that in the control group (72.7% vs 40.0%).No significant difference of TESS scores was found between the two groups.Conclusion:EA combined with Paroxetine has better clinical efficacy than that of Paroxetine alone,with milder adverse reaction and quicker initiation of effect.     

Clinical study on treatment of hyperuricaemia by retention enema of Chinese herbal medicine combined with allopurinol

Objective:To study the effect of retention enema of Chinese herbal medicine combined with allopurinol in treating hyperuricaemia(HUE).Methods:Seventy-eight patients with HUE were assigned to two groups,the 40 patients in the treated group were treated with retention enema of Chinese herbal medicine combined with oral intake of allopurinol,and the 38 patients in the control group were treated with allopurinol alone. The therapeutic course for all was 6 weeks.The clinical efficacy,changes of symptoms,blood...     

Clinical observation on the efficacy of Xiaoshui decoction (消水方) combined with intrapleural perfusion of cisplatin in treating malignant pleural effusion

Objective： To observe the clinical efficacy of Xiaoshui decoction （XSD,消水方） combined with intrapleural perfusion of cisplatin in the treatment of malignant pleural effusion. Methods： Fifty-one patients with malignant pleural effusion were randomly assigned to two groups. The treated group patients） received oral administration of XSD combined with intrapleural perfusion of cisplatin, and control group （25 patients） was only treated with intrapleural perfusion of cisplatin. The effects of 26 he he short-term efficacy, quality of life scores and clinical symptom scores of malignant pleural effusion were evaluated. Results： The short-term efficacy in the treated group and the control group was 72.0% and 58.3%, respectively, and no significant difference was found （P〉0.05）. In contrast, the quality of life in the treated group was significantly improved compared to that of the control group （P〈0.05）, and so was the symptom remission （P〈0.05）. Conclusions： The combined therapy of XSD and intrapleural perfusion of cisplatin did not show obvious improvement in short-term efficacy, but the therapy remarkably alleviated the symptoms and improved the quality of life of patients.     

Treatment of advanced non-small cell lung cancer with extracorporeal high frequency thermotherapy combined with Chinese medicine

Objective： To observe the clinical efficacy and benefit response of extracorporeal high frequency thermotherapy （EHFT） combined with Chinese medicine （CM） in the treatment of patients with advanced non-small cell lung cancer. Methods： The study adopted a prospective, small sample and randomized controlled method, and the advanced non-small cell lung cancer patients were assigned to two groups according to the table of random digits, one having the treatment of EHFT combined with CM （the treatment group）, the other only with CM （the control group）. The patients in the treatment group were treated with EHFT one hour once per day, together with CM differentiation decoction, 250 mL orally taken, twice daily for 14 days as one cycle, and 3-4 cycles was performed. The patients in the control group were treated only with CM differentiation decoction using the same dose as the treatment group. The efficacies were evaluated after three to four cycles of treatment. Primary endpoints were disease control rate （DCR） and time to progression （TTP）. Secondary endpoints were overall survival time and 1-year survival rate. Results： Sixty-six patients accomplished the study. After the patients underwent different treatments, none of the patients got a complete response or partial response in both groups. In the treatment group, DCR was 72.2%, and 10 had progression of disease （28.8%）, while the DCR of the control group was 63.3%, and 11 had progression of disease （36.7%）; there was a significant statistical difference （P0.05）, suggesting that the combined regimen had superiority on the DCR. As for long-term efficacy, the median survival time （MST） of the treatment group was 7.5 months, TTP was 5.5 months, and 1-year survival rate was 21.4 %; in the control group, the results were 6.8 months, 4.5 months and 16.6% respectively. There was significant statistical difference on TTP （P0.05）, but no difference on MST or 1-year survival rate. Conclusion： EHFT combined with CM differentiation has better tolerance and short-term efficacy in the treatment of patients with advanced NSCLC.     

Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma

Background Regional intra-arterial infusion chemotherapy （RIAC） has been more valuable to improve prognosis and quality of life of patients with inoperable pancreatic adenocarcinomas, and adjuvant RIAC plays an important role in prolonging survival and reducing risk of liver metastasis after radical resection of pancreatic cancer, but the effect of preoperative or multiple-phase RIAC （preoperative combined with postoperative RIAC） for resectable pancreatic cancers has not been investigated. In this prospective study, the effect of multiple-phase RIAC for patients with resectable pancreatic head adenocarcinoma was evaluated, and its safety and validity comparing with postoperative RIAC were also assessed. Methods Patients with resectable pancreatic head cancer were randomly assigned to two groups. Patients in group A （n=-50） were treated with new therapeutic mode of extended pancreaticoduodenectomy combined with multiple-phase RIAC, and those in group B （n=-50） were treated with extended pancreaticoduodenectomy combined with postoperative RIAC in the same period. The feasibility, compliance and efficiency of the new therapeutic mode were evaluated by tumor size, serum tumor markers, clinical benefit response （CBR）, surgical complications, mortality and toxicity of RIAC. The disease-free survival time, median survival time, incidence of liver metastasis, survival rate at 1, 2, 3 and 5 years were also observed. Life curves were generated by the Kaplan-Meier method. Results The pain relief rate and CBR in group A was 80% and 84% respectively. Serum tumor markers decreased obviously and tumors size decreased in 26% of patients after preoperative RIAC in group A. No more surgical complications, mortality or severe systemic side effects were observed in group A compared with group B. The incidence of liver metastasis in group A was 34% which was lower than 50% in group B. The disease-free survival time and median survival time in group A were 15.5 months and 18 months respectively. The 1-, 2-, 3- and 5-year survival rates were 54.87%, 34.94%, 24.51% and 12.25% respectively. There was no significant difference of survival time or survival rates between two groups. Conclusions Multiple-phase RIAC is effective in combined therapy of resectable pancreatic head carcinomas by enhancing inhibition of tumor growth and reduction of liver metastasis, without negative effect on patients＇ safety or surgical procedure.     

Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study

Background The primary objectives of the treatment for the lower urinary tract symptoms （LUTS） associated with benign prostatic hyperplasia （BPH） are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50. In this study, we evaluated the efficacy and safety of the combined therapy with terazosin （α1-adrenergic receptor antagonist） and tolterodine （anticholinergic agent） for LUTS associated with BPH. Methods This combination study included 69 patients diagnosed with LUTS associated with BPH based on the International Prostate Symptom Scores （IPSS）, urinary flow rate, prostate volume, urinary residual, and their serum prostate-specific antigen levels. Initially, 191 patients were treated with terazosin 2 mg once daily for one week. Those patients with continued LUTS after the initial treatment were allocated randomly into two groups： terazosin group （n=-36） in which patients were treated with terazosin 2 mg once daily for six weeks, and combination group （n=33） in which patients were treated with both terazosin 2 mg once daily and tolterodine 2 mg twice daily for 6 weeks. Results The IPSS were significantly improved in both groups after treatment, and the reduction of IPSS in the combination group was significantly greater than that in the terazosin group （P〈0.01）. A decrease in urgency, frequency and nocturia were the main contributory factors causing the reduction of IPSS in the combination group. The differences about the peak urinary flow rate and the residual urine from the baseline values were noted in both groups after treatment but were not significant between the two groups. The incidence of adverse effects in the combination group was higher than that in the terazosin group. As expected the most common adverse effect was mouth dryness which was associated with anticholinergic drugs such as tolterodine. Conclusions Patients with LUTS associated BPH appear the improved IPSS after combined therapy with terazosin and tolterodine. This study, although short term and limited numbers of patients, provides evidence that the combined therapy with terazosin plus tolterodine is a good approach for meeting the objectives of rapid, sustained, and safe improvements in the LUTS associated with BPH. And the profile of patients in this study might be used as the indication of such combined therapy for LUTS associated with BPH without urodynamic evaluation.     

Prognostic impact of splenectomy on advanced proximal gastric cancer with No. 10 lymph node metastasis

Background This study evaluated the prognostic impact of D2 lymphadenectomy combined with splenectomy in patients with advanced proximal gastric cancer and lymph node metastasis at the splenic hilum （No. 10 lymph nodes）. Methods The clinical records of 216 patients with advanced proximal gastric cancer and No. 10 lymph node metastasis who underwent D2 curative resection were retrospectively analyzed. Seventy-three patients underwent simultaneous splenectomy （splenectomy group）, while 143 patients did not （spleen-preserving group）. Five-year survival rates, mean numbers of dissected No. 10 lymph nodes and metastatic No. 10 lymph nodes, and operative morbidity and mortality were calculated and compared between the two groups. Potential prognostic factors were evaluated by univariate and multivariate analysis.
Results The 5-year survival rate was 30.0% for the splenectomy group and 19.7% for the spleen-preserving group （χ^2=14.73, P 〈0.05）. The mean numbers of dissected No. 10 lymph nodes and metastatic No. 10 lymph nodes in the splenectomy group were significantly greater than in the spleen-preserving group （P 〈0.05）. Multivariate analysis revealed that the depth of invasion, splenectomy, and type of gastrectomy were independent prognostic factors. The survival rate for T3 patients with and without splenectomy was 38.7% and 18.9%, respectively （χ^2 =15.03, P 〈0.05）. For patients undergoing total gastrectomy, survival rates were 33.4% and 20.7%, respectively （χ^2 =13.63, P〈0.05）. Operative morbidity and mortality in splenectomy group was 24.7% and 4.1%, respectively, and in the spleen-preserving group was 17.5% and 3.5%, respectively. The differences were not statistically significant （P 〉0.05）. Conclusions Splenectomy is beneficial for No. 10 lymph node dissection in patients with advanced proximal gastric cancer. To improve patient prognosis, total gastrectomy with splenectomy is recommended for patients with T3 proximal gastric cancer who have No. 10 lymph node metastasis.     

An Experimental Study of the Protective Effects of Chinese Medicine Compound Eye-Patch on Asthenopia

Objective:To observe the therapeutic efficacy and the mechanism of Chinese medicine eye-patch with invigorating blood circulation and detoxification on asthenopia.Methods:A total of 180 rabbits were subjected to three tests,namely the skin microcirculation,the microvascular regeneration in the skin and the skin temperature change,with 60 rabbits for each test.The rabbits in each test were randomly and equally divided into three groups: the normal control group was treated with physiological saline on naked back once per day,the low dose group was treated with the eye-patch on naked back for 15 min once per day,while the high dose group was treated for three times per day.Forty Hartley guinea pigs were randomly and equally divided into four groups for the muscle tone test:the normal control group was treated with physiological saline on naked back,the model group was treated without any medication,the low dose group was treated with the eye-patch on naked back for 10 min once per day, while the high dose group was treated for three times per day.All treatments were continued for 14 days until the termination of the test.The microcirculatory blood flow was observed by using a video-microscopy system.The histological sections were used to detect the microvascular regeneration by observing the expression of factorⅧ. The temperature changes on the skin surface were measured by using infrared thermometer,and the muscle tone was tested by the electromyography.Results:In compare with the normal or the model group,the improvement in the skin microcirculation and the blood vascular regeneration,and the decreasing in the muscle tone in low dose and high dose groups were statistically significant with confident level at P<0.05.Conclusions:The eye-patch with invigorating blood circulation and detoxification has great enhancement in blood vascular regeneration and skin microcirculation,and great improvement in the indexes for muscle tone.The study explains certain therapeutic efficacy and mechanism of the eye-patch and shows that it could reduce the symptoms for patients with asthenopia.     

解脲支原体感染与妊娠结局的临床分析

目的　了解解脲支原体Uu感染与胚胎停止发育的关系。方法　 1 2 0例早孕妇女分为 2组 ,有胚胎发育停止史的 70例为观察组 ,正常人工流产的 50例为对照组。应用金标免疫斑点法检测1 2 0例早孕妇女血清中的解脲支原体抗体 (Uu Ab) ,同时采用B型超声波检查了解胚胎发育情况 ,进行探讨。结果　检测 2组Uu Ab发现 ,观察组Uu Ab阳性率为 48.6 % ,对照组为 2 2 .0 % ,2组比较差异显著(P <0 .0 5) ,胚胎停止发育次数与Uu Ab阳性率呈正相关系。结论　Uu Ab检测在临床上可作为Uu感染的辅助诊断指标 ,胚胎停止发育与Uu感染密切相关系     

尿路清对解脲支原体国际标准株和临床耐药菌株的抑菌作用

[目的]探讨中药尿路清(由白花蛇舌草、土茯苓、地肤子、黄柏、崩大碗等组成)对解脲支原体(Uu)的抑菌作用。[方法]以测定药物抑制微生物的最低浓度(MIC)的方法测定尿路清对解脲支原体(Uu)国际标准菌株和临床菌株的敏感性,并以红霉素和四环素做对比,测定63株Uu临床菌株分别对尿路清、红霉素、四环素的敏感性,以判断菌株对尿路清的耐药情况。[结果]尿路清对解脲支原体(Uu)国际标准株(T8)的MIC为7.81mg/mL。63株Uu临床菌株中,31株为四环素耐药株,13株为红霉素耐药株,经统计学检验,Uu临床株对尿路清的敏感性分别与对四环素和红霉素的敏感性之间无明显联系(x2=1.85,P>0.05;x2=1.24,P>0.05),对四环素和对红霉素耐药者并不。定对尿路清耐药。[结论]中药尿路清时Uu国际标准株(T8)显示出较强的体外抑菌作用,对临床耐红霉素、四环素的Uu菌株亦敏感。     

非淋菌性尿道炎患者衣原体和支原体的感染状况分析

目的 探讨非淋菌性尿道炎(NGU)患者沙眼衣原体(CT)和解脲支原体(Uu)的感染状况.方法 CT检测采用快速免疫测定法,Uu采用病原体培养法.结果 640例NGU患者CT阳性率为34.15%,Uu 40.85%,二者混合感染率23.44%.男、女性患者CT、Uu检出率差异均有统计学意义(P＜0.05),其中CT感染为男性高于女性,Uu为女性高于男性(P＜0.01).对照组CT检出率3.75%,Uu培养结果均为阴性.结论 NGU患者CT和Uu的感染率较高,对NGU患者应同时检测CT和Uu,将有助于该病的及时防治.     

男性不育症患者解脲脲原体感染情况与精液检查结果分析

目的探讨解脲脲原体感染与男性不育症的关系以及其对不育症患者精液检查结果的影响。方法对2017年5~10月于大理大学第一附属医院就诊的362例男性不育症患者和同期于我院进行健康体检的100例已生育男性精液的解脲脲原体感染情况、精液常规情况、血清抗精子抗体情况以及精子DNA碎片化指数进行检测和分析。结果不育组解脲脲原体阳性率为39.0%,显著高于对照组(P0.05);对照组解脲脲原体阴性者的精液常规检查结果明显优于不育组解脲脲原体阳性者(P0.05);不育组UU阳性者血清抗精子抗体检出率(38.3%)和DNA碎片化指数(14.9%)显著高于对照组UU阴性者(P0.05)。结论解脲脲原体感染可通过降低男性精液质量、诱导抗精子抗体产生和损伤精子DNA完整性而影响男性的生育功能。     

非淋菌性尿道炎女性解脲支原体感染情况及药敏趋势分析

目的:了解2009～2011年威海地区解脲支原体引起的女性非淋菌性尿道炎感染现状及其药物敏感情况,为生殖道支原体感染的防治提供科学依据。方法:采用支原体培养、鉴定及药敏一体化试剂盒对女性生殖道感染患者进行检测。用SPSS11.0统计软件包进行统计学分析。结果:1288例疑似支原体感染的女性中,单纯解脲支原体阳性604例,检出率为46.89%。药敏试验结果显示,解脲支原体对8种抗生素的敏感性从高到低分别为交沙霉素(99.34%)、强力霉素(98.68%)、四环素(96.03%)、克拉霉素(92.55%)、阿奇霉素(79.80%)、红霉素(79.47%)、氧氟沙星(18.38%)、环丙沙星(9.44%)。结论:解脲支原体感染率3年来并无变化,同时对应的药物敏感性也无变化。交沙霉素和强力霉素可作为首选用药。但对支原体感染的治疗,仍要根据药物敏试验结果合理选用抗生素,降低耐药菌株的产生。     

抗菌药物对解脲支原体作用的实验室研究

目的 :探讨解脲支原体 (Uu)对抗生素的敏感性。方法 :采用肉汤稀释法对 6 5株Uu进行了体外敏感性测定。结果 :大环内酯类药物 ,尤其是罗红霉素对Uu的体外抑制作用最强 ,MIC50 和MIC90 分别是 1mg/L和 2mg/L ,而红霉素分别为 2mg/L和 8mg/L ;喹诺酮类、左旋氟嗪酸MIC50 和MIC90 分别为 2mg/L和 4mg/L ,而氟嗪酸分别为4mg/L和 8mg/L ;四环素类、强力霉素对Uu抑制效果较好 ,MIC50 和MIC90 分别为 2mg/L和 4mg/L ,8株Uu对四环素高度耐药 ,其MIC50 与MIC90 是 6 4mg/L和 12 8mg/L。结论 :大环内酯类药物是目前治疗Uu感染的首选药物 ,其次为左旋氟嗪酸和强力霉素。     

克拉霉素与鱼腥草联合治疗解脲支原体阴道炎疗效观察

目的 探讨克拉霉素和鱼腥草联合治疗女性解脲支原体阴道炎的临床价值。方法 实验组77例解脲支原体阴道炎患者采用克拉霉素和鱼腥草注射液二联疗法;对照组90例患者单用克拉霉素治疗,全部用药14天,比较两组的疗效。结果 实验组患者的治愈率为66％,显著高于对照组48％的治愈率（P〈0.05）。结论 克拉霉素配合鱼腥草中西药联合治疗解脲支原体阴道炎是一种较为理想的治疗方法,值得临床推广。     

解脲支原体对女性生殖道致病性的临床分析

目的： 探讨解脲支原体（UU）与女性年龄、妊娠史、宫内节育器（IUD）、宫颈炎及阴道炎之间的关系.方法：记录109例普通妇科门诊患者的年龄、妊娠史、IUD、宫颈炎及阴道炎等情况,取宫颈拭子作UU液体培养,取阴道分泌物作白带常规化验.分析UU检出率与年龄、妊娠史、IUD、宫颈炎、阴道炎的关系.结果：UU液体培养结果在不同年龄、妊娠史、IUD、宫颈炎及阴道炎患者间的差异无统计学意义（P〉0.05）.结论：UU在宫颈可保持无任何病理改变的携带状态,与患者的年龄、妊娠史、IUD、宫颈炎及阴道炎无关.     

解脲支原体感染及耐药性变化分析

目的分析我院2008—2010年泌尿生殖系炎症患者解脲支原体(Uu)感染及耐药性变化情况,为临床提供最新的流行病学资料及指导用药。方法采用支原体培养、药敏一体化方法检测我院妇科、皮肤科送检的泌尿生殖道分泌物,回顾性分析Uu培养和药敏试验结果等资料。结果 2008—2010年Uu总阳性检出率分别为46.04%、45.97%、48.77%,3年Uu阳性检出率差异无统计学意义(P>0.05);大环内酯类:红霉素耐药率2010年较2008年、2009年明显下降(P<0.01),罗红霉素耐药率有逐渐上升趋势,但差异无统计学意义(P>0.05),阿奇霉素、克拉霉素耐药率有逐渐下降趋势,但差异无统计学意义(P>0.05),交沙霉素3年中具有比较恒定的低耐药性;喹诺酮类:环丙沙星耐药率有逐渐上升趋势,但差异无统计学意义(P>0.05),司帕沙星、氧氟沙星、左氧氟沙星耐药率2010年较2008年、2009年明显下降(P<0.01);四环素类中的美满霉素和强力霉素均表现较高敏感性,3年内耐药率变化差异无统计学意义(P>0.05)。结论 3年来Uu在本地区的流行病学变化较小。对泌尿生殖道Uu感染经验治疗可以使用交沙霉素、美满霉素和强力霉素,应用其他抗菌药物时应以药敏结果做为参考。     

宫内解脲支原体感染与新生儿出生体重

目的 :研究孕妇宫内感染解脲支原体 (Uu)后对新生儿出生体重的影响。方法 :利用 PCR技术检测 46例足月新生儿胎盘组织、脐静脉血及咽吸出物中解脲支原体感染状况。结果 :Uu+的胎盘平均重量与 Uu-的胎盘平均重量相比差异显著 (P<0 .0 5)。胎盘 Uu+的足月新生儿平均出生体重较 Uu-的足月新生儿平均出生体重低 41 1 g,差异显著 (P<0 .0 5)。足月小样儿胎盘 Uu感染率为75% (3/4) ,而足月正常儿胎盘 Uu感染率为 2 1 .43% ,差异显著 (P=0 .0 4 9)。咽吸出物、脐血 Uu+的足月新生儿平均体重虽然较 Uu-组低 ,但无显著差异。结论 :宫内胎盘 Uu感染可致新生儿出生体重降低